JPH09506873A - 成長ホルモン放出性を有する化合物 - Google Patents
成長ホルモン放出性を有する化合物Info
- Publication number
- JPH09506873A JPH09506873A JP7517110A JP51711095A JPH09506873A JP H09506873 A JPH09506873 A JP H09506873A JP 7517110 A JP7517110 A JP 7517110A JP 51711095 A JP51711095 A JP 51711095A JP H09506873 A JPH09506873 A JP H09506873A
- Authority
- JP
- Japan
- Prior art keywords
- ala
- trp
- phe
- 2nal
- imidazolyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth-hormone releasing factors (GH-RF) (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.一般式I: A−B−C−D−E(−F)p (I) (式中、pは0又は1であり; Aはイミダゾリル−C1-6アルカン酸、イミダゾリル−C1-6アルケン酸、アミ ノ−C1-6アルカン酸又はアミノ−C1-6アルケン酸、又はH−His,H−Ala,H −D−Ala,H−β−アラニン、H−アミノ−イソ酪酸、サルコシンおよびGlyか ら成る群から選ばれるL−もしくはD−α−アミノ酸であり; BはD−Trp,D−2Nal又はD−Pheであり; CはAla,Ser又はGlyであり; DはTrp,Phe,β−(2−チエニル)−アラニン、又はN−アラルキルグリシ ンであり; Eはpが1であるとき、D−Pheであるか、又はpが0であるときEは-NH-CH( CH2-R3)-CO-R4又は-NH-CH(CH2-R3)-CH2-R4であり、ここでR3はフェニルであり 、そしてR4はピペラジノ、モルホリノ、ピペリジノ、−OH又は−N(R5)R6であり 、ここでR5およびR6の各々は独立に水素又は低級アルキルであり; Fはpが1であるとき-NH-CH(R10)-(CH2)v-R7)-であり、ここで vは0又は1〜8の整数であり、そして R7はイミダゾリル、ピペラジノ、モルホリノ、ピペリジノ又は-N(R8)-R9(こ こで、R8およびR9の各々は独立に水素又は低級アルキルである)、又はアミノ 基およびヘキサピラノース又は次式 のヘキサピラノシル−ヘキサピラノースからのアマドリ転位生成物であり、そし て R10は−H,−COOH,−CO−R11,CH2−R11又は-CH2-OHであり、ここでR11は ピペラジノ、モルホリノ、ピペリジノ又は−N(R12)−R13であり、ここでR12お よびR13の各々は独立に水素又は低級アルキルであり; 但し、AとB、BとC、CとD、DとE又はpが1であるとき、EとF間の少 なくとも1つのアミド結合はアミノメチレンにより置換されているか又はpが0 であるとき、Eは-NH-CH(CH2-R3)-CH2-R4であるか又はpが1であるとき、R10 はCH2-R11である) で表わされる化合物又はその医薬として許容し得る塩。 2.pが1である、請求の範囲第1項記載の化合物。 3.AがHis、D−Ala又はイミダゾリルプロピオン酸である、請求の範囲第1 項記載の化合物。 4.BがD−Trp又はD−2Nalである、請求の範囲第1項記載の化合物。 5.CがAlaである、請求の範囲第1項記載の化合物。 6.DがN−ベンジルグリシン又はTrpである、請求の範囲第1項記載の化合 物。 7.EがD−Pheである、請求の範囲第1項記載の化合物。 8.vが6でありそしてR7が−NH2である、請求の範囲第1項記載の化合物。 9.R10が−CONH2,-CH2-OHである、請求の範囲第1項記載の化合物。 10.H-HisΨ(CH2NH)D-Trp-Ala-Trp-D-Phe-Lys-NH2 H-His-D-TrpΨ(CH2NH)Ala-Trp-D-Phe-Lys-NH2 H-His-D-Trp-AlaΨ(CH2NH)Trp-D-Phe-Lys-NH2 H-His-D-Trp-Ala-TrpΨ(CH2NH)D-Phe-Lys-NH2 H-His-D-Trp-Ala-Trp-D-PheΨ(CH2NH)Lys-NH2 H-D-Ala-D-2Nal-AlaΨ(CH2NH)Trp-D-Phe-Lys-NH2 H-D-Ala-D-2Nal-Ala-Trp-D-PheΨ(CH2NH)Lys-NH2 (3-(4-イミダゾリル)プロピオニル)-D-2Nal-Ala-Trp-D-PheΨ(CH2NH)Lys-OH (3-(4-イミダゾリル)プロピオニル)-D-2Nal-Ala-Trp-D-PheΨ(CH2NH)Lys-NH2 (3-(4-イミダゾリル)アクリロイル)-D-2Nal-Ala-Trp-D-PheΨ(CH2NH)Lys-NH2 H-D-Ala-D-Phe-Ala-Trp-D-PheΨ(CH2NH)Lys-NH2 (2R)-(H-D-Ala-D-Phe-Ala-Trp-NH)-3-フェニルプロピルアミン (2S)-(H-D-Ala-D-2Nal-AlaΨ(CH2NH)Trp-D-Phe-NH)-6-アミノヘキサノール H-D-Ala-D-2Nal-AlaΨ(CH2NH)Trp-D-Phe-NH2 4-(H-D-Ala-D-2Nal-AlaΨ(CH2NH)Trp-D-Phe-NH)ブチルアミン (2R)-(H-D-Ala-D-2Nal-Ala-Trp-NH)-3-フェニルプロピルアミン ((2R)-(H-D-Ala-D-2Nal-Ala-Trp-NH)-3-フェニルプロピルアミノ)ヘキシルア ミン (2R)-(H-D-2Nal-Ala-N-Bzl-Gly-NH)-3-フェニルプロピルアミン (2R)-(H-D-Ala-D-2Nal-Ala-N-Bzl-Gly-NH)-3-フェニルプロピルアミン H-Aib-D-2Nal-Ala-N-Bzl-Gly-D-PheΨ(CH2NH)Lys-NH2 (2S)-((3-(4-イミダゾリル)プロピオニル)Ψ(CH2NH)D-phe-Ala-Trp-D-Phe-NH) -6-アミノヘキサノール (2S)-((3-(4-イミダゾリル)プロピオニル)-D-PheΨ(CH2NH)Ala-Trp-D-Phe-NH) -6-アミノヘキサノール (2S)-((3-(4-イミダゾリル)プロピオニル)-D-Phe-AlaΨ(CH2NH)Trp-D-Phe-NH) -6-アミノヘキサノール (2S)-((3-(4-イミダゾリル)プロピオニル)-D-Phe-Ala-TrpΨ(CH2NH)D-Phe-NH) -6-アミノヘキサノール (2S)-(2R)-((3-(4-イミダゾリル)プロピオニル)-D-Phe-Ala-Trp-NH)-3-フェニ ルプロピルアミノ)-6-アミノヘキサノール 3-((3-(4-イミダゾリル)プロピオニル)-D-Trp-Ala-Ψ(CH2NH)Trp-D-Phe-NH)プ ロピルアミン (2S)-((3-(4-イミダゾリル)プロピオニル)-D-Phe-Ala-Trp-D-PheΨ(CH2NH)NH) -6-アミノヘキサノール (2S)-((3-(4-イミダゾリル)プロピオニル)-D-Trp-AlaΨ(CH2NH)Trp-D-Phe-NH) -6-アミノヘキサノール 3-((3-(4-イミダゾリル)プロピオニル)-D-Trp-AlaΨ(CH2NH)Trp-D-Phe-NH)プ ロピルアミン H-D-Ala-D-2Nal-Ala-N-Bzl-Gly-D-PheΨ(CH2NH)Lys-NH2 H-Alb-D-2Nal-Ala-N-Bzl-Gly-D-PheΨ(CH2NH2) から成る群から選ばれる、請求の範囲第1〜9項のいずれか1項に記載の化合 物。 11.活性成分として一般式Iの化合物又はその医薬として許容され得る塩並び に医薬として許容され得る担体又は希釈剤を含んでな る医薬組成物。 12.約10mg〜約200mgの一般式Iの化合物又はその医薬として許容され得る塩 を含んでなる、単位剤形にある請求の範囲第11項記載の医薬組成物。 13.下垂体からの成長ホルモンの放出を刺激する医薬組成物であって、活性成 分として一般式Iの化合物又はその医薬として許容され得る塩並びに医薬として 許容され得る担体又は希釈剤を含んでなる、前記医薬組成物。 14.下垂体から成長ホルモンの放出を刺激する方法であて、有効量の一般式I の化合物又はその医薬として許容され得る塩を、それを必要とする被験者に投与 することを含んでなる、前記方法。 15.有効量の一般式Iの化合物又はその医薬として許容され得る塩又はエステ ルが、体重1kg当たり一日当たり約0.0001〜約100mgの範囲内、好ましくは体重 1kg当たり1日当たり約0.001〜約50mgの範囲内にある、請求の範囲第14項記載 の方法。 16.下垂体から成長ホルモンの放出を刺激するための医薬の製造のための一般 式Iの化合物又はその医薬として許容され得る塩の使用。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK1438/93 | 1993-12-23 | ||
DK143893A DK143893D0 (ja) | 1993-12-23 | 1993-12-23 | |
DK7594 | 1994-01-17 | ||
DK0075/94 | 1994-01-17 | ||
DK0781/94 | 1994-06-30 | ||
DK78194 | 1994-06-30 | ||
DK1165/94 | 1994-10-07 | ||
DK116594 | 1994-10-07 | ||
PCT/DK1994/000486 WO1995017422A1 (en) | 1993-12-23 | 1994-12-22 | Compounds with growth hormone releasing properties |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09506873A true JPH09506873A (ja) | 1997-07-08 |
JP3759748B2 JP3759748B2 (ja) | 2006-03-29 |
Family
ID=27439242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51711095A Expired - Fee Related JP3759748B2 (ja) | 1993-12-23 | 1994-12-22 | 成長ホルモン放出性を有する化合物 |
Country Status (18)
Country | Link |
---|---|
US (1) | US5854211A (ja) |
EP (1) | EP0736038B1 (ja) |
JP (1) | JP3759748B2 (ja) |
CN (1) | CN1052730C (ja) |
AT (1) | ATE202785T1 (ja) |
AU (1) | AU683121B2 (ja) |
CA (1) | CA2179598A1 (ja) |
CZ (1) | CZ291382B6 (ja) |
DE (1) | DE69427650T2 (ja) |
FI (1) | FI962591A0 (ja) |
HU (1) | HU221092B1 (ja) |
IL (1) | IL112111A (ja) |
NO (1) | NO315611B1 (ja) |
PL (1) | PL181286B1 (ja) |
RU (1) | RU2167881C2 (ja) |
TW (1) | TW438810B (ja) |
UA (1) | UA45962C2 (ja) |
WO (1) | WO1995017422A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003517294A (ja) * | 1999-07-26 | 2003-05-27 | ベイラー カレッジ オブ メディスン | 超高活性ブタ成長ホルモン放出ホルモン類似体 |
US10386569B2 (en) | 2015-02-10 | 2019-08-20 | Fujifilm Corporation | Optical member, optical element, liquid crystal display device, and near-to-eye optical member |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995014666A1 (en) * | 1993-11-24 | 1995-06-01 | Merck & Co., Inc. | Indolyl group containing compounds and the use thereof to promote the release of growth hormone(s) |
US6531314B1 (en) | 1996-12-10 | 2003-03-11 | Merck & Co., Inc. | Growth hormone secretagogue receptor family |
JP3798024B2 (ja) | 1995-12-13 | 2006-07-19 | メルク エンド カンパニー インコーポレーテッド | 成長ホルモン分泌促進物質レセプターアッセイ |
GB2308362A (en) * | 1995-12-19 | 1997-06-25 | Lilly Industries Ltd | Pharmaceutical indole derivatives |
US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
US6420518B1 (en) | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
AU7906998A (en) | 1997-06-20 | 1999-01-04 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
DE69921611T2 (de) | 1998-01-16 | 2005-11-03 | Novo Nordisk A/S | Verbindungen mit wachstumshormon-freisetzenden eigenschaften |
US6682908B1 (en) | 1998-07-10 | 2004-01-27 | Merck & Co., Inc. | Mouse growth hormone secretagogue receptor |
WO2000002919A1 (en) | 1998-07-13 | 2000-01-20 | Merck & Co., Inc. | Growth hormone secretagogue related receptors and nucleic acids |
EP1112282A4 (en) | 1998-08-10 | 2002-10-31 | Merck & Co Inc | RECEPTOR OF THE GROWTH HORMONE SECRETION PROMOTER FROM THE DOG |
IL143866A0 (en) | 1999-01-06 | 2002-04-21 | Genentech Inc | Insulin-like growth factor (igf) i mutant variants |
KR100699404B1 (ko) | 1999-02-18 | 2007-03-23 | 가켄 세야쿠 가부시키가이샤 | 성장 호르몬 분비촉진제로서의 신규 아미드 유도체 |
AU5630800A (en) * | 1999-06-22 | 2001-01-09 | Arno F Spatola | Antimicrobial agents |
EP1265849B1 (en) * | 2000-03-23 | 2006-10-25 | Elan Pharmaceuticals, Inc. | Compounds and methods to treat alzheimer's disease |
AU2001263215A1 (en) | 2000-05-16 | 2001-11-26 | Genentech Inc. | Method for treating cartilage disorders |
EP1159964B1 (en) | 2000-05-31 | 2009-10-28 | Pfizer Products Inc. | Use of growth hormone secretagogues for stimulating gastrointestinal motility |
US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
DK2274978T3 (en) | 2003-09-12 | 2015-06-15 | Ipsen Biopharmaceuticals Inc | Methods of treating an insulin-like growth factor-I (IGF-I) deficiency |
WO2005027913A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
BRPI0807046A2 (pt) | 2007-02-09 | 2015-05-26 | Tranzyme Pharma Inc | Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit. |
WO2008134828A2 (en) | 2007-05-04 | 2008-11-13 | Katholieke Universiteit Leuven | Tissue degeneration protection |
WO2013190520A2 (en) | 2012-06-22 | 2013-12-27 | The General Hospital Corporation | Gh-releasing agents in the treatment of vascular stenosis and associated conditions |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
RU2016146826A (ru) | 2014-05-30 | 2018-07-04 | Пфайзер Инк. | Производные карбонитрилов как селективные модуляторы андрогенового рецептора |
US20170121385A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4803261A (en) * | 1986-06-27 | 1989-02-07 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide |
US5480869A (en) * | 1990-01-09 | 1996-01-02 | The Regents Of The University Of California | Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues |
US5486505A (en) * | 1990-07-24 | 1996-01-23 | Polygen Holding Corporation | Polypeptide compounds having growth hormone releasing activity |
IL98910A0 (en) * | 1990-07-24 | 1992-07-15 | Polygen Holding Corp | Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them |
US5663146A (en) * | 1991-08-22 | 1997-09-02 | Administrators Of The Tulane Educational Fund | Polypeptide analogues having growth hormone releasing activity |
US5470753A (en) * | 1992-09-03 | 1995-11-28 | Selectide Corporation | Peptide sequencing using mass spectrometry |
SE9300012D0 (sv) * | 1993-01-05 | 1993-01-05 | Astra Ab | New peptides |
US5559209A (en) * | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
WO1995017423A1 (en) * | 1993-12-23 | 1995-06-29 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
-
1994
- 1994-12-22 CA CA002179598A patent/CA2179598A1/en not_active Abandoned
- 1994-12-22 US US08/464,679 patent/US5854211A/en not_active Expired - Fee Related
- 1994-12-22 EP EP95904405A patent/EP0736038B1/en not_active Expired - Lifetime
- 1994-12-22 WO PCT/DK1994/000486 patent/WO1995017422A1/en active IP Right Grant
- 1994-12-22 RU RU96115195/04A patent/RU2167881C2/ru not_active IP Right Cessation
- 1994-12-22 PL PL94315114A patent/PL181286B1/pl not_active IP Right Cessation
- 1994-12-22 AT AT95904405T patent/ATE202785T1/de active
- 1994-12-22 HU HU9601740A patent/HU221092B1/hu not_active IP Right Cessation
- 1994-12-22 CN CN94194588A patent/CN1052730C/zh not_active Expired - Fee Related
- 1994-12-22 AU AU13106/95A patent/AU683121B2/en not_active Ceased
- 1994-12-22 UA UA96062484A patent/UA45962C2/uk unknown
- 1994-12-22 DE DE69427650T patent/DE69427650T2/de not_active Expired - Fee Related
- 1994-12-22 IL IL11211194A patent/IL112111A/xx not_active IP Right Cessation
- 1994-12-22 CZ CZ19961833A patent/CZ291382B6/cs not_active IP Right Cessation
- 1994-12-22 JP JP51711095A patent/JP3759748B2/ja not_active Expired - Fee Related
-
1995
- 1995-01-13 TW TW084100272A patent/TW438810B/zh active
-
1996
- 1996-06-20 FI FI962591A patent/FI962591A0/fi not_active IP Right Cessation
- 1996-06-21 NO NO19962664A patent/NO315611B1/no not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003517294A (ja) * | 1999-07-26 | 2003-05-27 | ベイラー カレッジ オブ メディスン | 超高活性ブタ成長ホルモン放出ホルモン類似体 |
JP4644402B2 (ja) * | 1999-07-26 | 2011-03-02 | ベイラー カレッジ オブ メディスン | 超高活性ブタ成長ホルモン放出ホルモン類似体 |
US10386569B2 (en) | 2015-02-10 | 2019-08-20 | Fujifilm Corporation | Optical member, optical element, liquid crystal display device, and near-to-eye optical member |
Also Published As
Publication number | Publication date |
---|---|
RU2167881C2 (ru) | 2001-05-27 |
WO1995017422A1 (en) | 1995-06-29 |
NO315611B1 (no) | 2003-09-29 |
HU9601740D0 (en) | 1996-08-28 |
US5854211A (en) | 1998-12-29 |
HUT74820A (en) | 1997-02-28 |
EP0736038B1 (en) | 2001-07-04 |
CZ183396A3 (en) | 1997-02-12 |
AU683121B2 (en) | 1997-10-30 |
PL315114A1 (en) | 1996-10-14 |
FI962591A (fi) | 1996-06-20 |
DE69427650T2 (de) | 2001-11-22 |
CN1138334A (zh) | 1996-12-18 |
DE69427650D1 (de) | 2001-08-09 |
CZ291382B6 (cs) | 2003-02-12 |
CN1052730C (zh) | 2000-05-24 |
AU1310695A (en) | 1995-07-10 |
FI962591A0 (fi) | 1996-06-20 |
EP0736038A1 (en) | 1996-10-09 |
JP3759748B2 (ja) | 2006-03-29 |
HU221092B1 (en) | 2002-08-28 |
IL112111A0 (en) | 1995-03-15 |
NO962664D0 (no) | 1996-06-21 |
CA2179598A1 (en) | 1995-06-29 |
ATE202785T1 (de) | 2001-07-15 |
UA45962C2 (uk) | 2002-05-15 |
TW438810B (en) | 2001-06-07 |
NO962664L (no) | 1996-08-23 |
PL181286B1 (pl) | 2001-07-31 |
IL112111A (en) | 2000-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3759748B2 (ja) | 成長ホルモン放出性を有する化合物 | |
JP3181918B2 (ja) | 成長ホルモン放出特性を持つ化合物 | |
US5939386A (en) | Chimeric fatty body-pro-GRF (1-29) analogs with increased biological potency | |
JPH11503454A (ja) | 成長ホルモン放出因子の類似体 | |
KR100225679B1 (ko) | 노나펩티드 봄베신 길항제 | |
JP2001508439A (ja) | 副甲状腺ホルモンの類似体 | |
CZ408197A3 (cs) | Peptidový derivát, farmaceutický prostředek ho obsahující, jejich použití, způsob stimulace uvolňování růstového hormonu a způsob zvýšení rychlosti a rozsahu růstu zvířat, zvýšení produkce mléka nebo vlny zvířat nebo léčení onemocnění | |
EP1309613B1 (en) | Pharmaceutical composition comprising an analgesic peptide | |
JPH08509960A (ja) | 骨原性成長オリゴペプチドおよびそれを含む医薬組成物 | |
JP2001524454A (ja) | 治療方法 | |
TW438811B (en) | Compounds with growth hormone releasing properties | |
JP4173541B6 (ja) | 成長ホルモン放出特性を有する化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040420 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040716 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040830 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041020 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050621 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050920 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20051006 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051025 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051101 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20051206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060105 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090113 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110113 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120113 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |